

Review

Botulinum Toxin Type A—A Modulator of Spinal Neuron–Glia Interactions under Neuropathic Pain Conditions

Ewelina Rojewska, Anna Piotrowska, Katarzyna Popiolek-Barczyk and Joanna Mika *

Department of Pain Pharmacology Institute of Pharmacology, Polish Academy of Sciences, 31-343 Krakow, Poland; rojewska@if-pan.krakow.pl (E.R.); anna.piotrowskamurzyn@gmail.com (A.P.); popiolek@if-pan.krakow.pl (K.P.-B.)

* Correspondence: joasia272@onet.eu

Received: 9 March 2018; Accepted: 30 March 2018; Published: 2 April 2018



Abstract: Neuropathic pain represents a significant clinical problem because it is a chronic condition often refractory to available therapy. Therefore, there is still a strong need for new analgesics. Botulinum neurotoxin A (BoNT/A) is used to treat a variety of clinical diseases associated with pain. Glia are in continuous bi-directional communication with neurons to direct the formation and refinement of synaptic connectivity. This review addresses the effects of BoNT/A on the relationship between glia and neurons under neuropathic pain. The inhibitory action of BoNT/A on synaptic vesicle fusion that blocks the release of miscellaneous pain-related neurotransmitters is known. However, increasing evidence suggests that the analgesic effect of BoNT/A is mediated through neurons and glial cells, especially microglia. In vitro studies provide evidence that BoNT/A exerts its anti-inflammatory effect by diminishing NF- κ B, p38 and ERK1/2 phosphorylation in microglia and directly interacts with Toll-like receptor 2 (TLR2). Furthermore, BoNT/A appears to have no more than a slight effect on astroglia. The full activation of TLR2 in astroglia appears to require the presence of functional TLR4 in microglia, emphasizing the significant interaction between those cell types. In this review, we discuss whether and how BoNT/A affects the spinal neuron–glia interaction and reduces the development of neuropathy.

Keywords: BoNT/A; astroglia; interleukins; microglia; TLR2; TLR4; Snap-23

1. The Therapeutic Effect of Bont/A—Powerful Analgesic Agent against Neuropathic Pain

Neuropathic pain is caused by damage or injury to the nerves, and it is commonly experienced in the human and animal populations, involving a huge number of pathological conditions. Recent clinical and experimental research has shown that neuroimmune factors significantly influence the modulation of the pain development process [1–4]. The mechanism of the development and persistence of chronic pain remains an important clinical problem. Current knowledge does not allow us to fully assess the process and identify its most crucial elements. As suggested by data available from the International Association for the Study of Pain, one out of every five Europeans suffers from chronic pain of various origins and must make lifestyle changes for that reason. An additional problem is posed by the lack of appropriate therapy for these disorders. The treatment of neuropathic pain is a therapeutic challenge, and many pharmacological and non-pharmacological interventions have been suggested, with unsatisfying results [5–9]. Pharmacological medicaments include non-steroidal anti-inflammatory drugs, antidepressants, anticonvulsants, and opioids [6]. However, their use increases the risk of adverse events, as well as reductions in analgesic efficacy. The mechanism of this loss in efficacy is also not sufficiently understood to fully counteract this phenomenon and

effectively treat pain. More effective treatments based on new targets and mechanisms of action are still being sought. This is the case for botulinum toxin A (BoNT/A), the use and application of which is increasing and becoming more widespread with time. BoNT/A is one of seven different BoNT types originating from *Clostridium botulinum* and is the most poisonous substance known to man [10], but, paradoxically, it has been widely used in the clinic, and its importance as a therapeutic agent is rising [11–18]. The well-defined mechanism of BoNT/A action is based on preventing release of the neurotransmitter acetylcholine from presynaptic nerve terminals through fragmentation of the protein SNAP-25 [19]. BoNT/A inhibits the release not only of acetylcholine but also of other neurotransmitters and neuropeptides, such as substance P and the calcitonin gene-related peptide (CGRP) [20–22]. The toxin also blocks conductivity in the autonomic system through sensory fibers and reduces the majority of substances acting on nociceptors [23]. Therefore, scientists are using it for clinical applications, including therapy for neuropathic pain.

BoNT/A has been used in medical practice since 1989, when it was first included in the medication list by The Food and Drug Administration in the United States. A year later, the report of the American Academy of Neurology stated that BoNT/A injections are efficient in treating blepharospasms, facial spasticity, tremor, hyperhidrosis, hypersalivation, and wrinkle correction [24]. The evidence for the efficacy of BoNT/A in neuropathic pain relief in humans was first presented by Klein in 2004 [25] in relation to neuropathic pain linked to multiple sclerosis, neuralgia and peripheral neuropathy. BoNT/A has been successfully used in clinical practice for the treatment of many types of headaches [16,26], migraine [14,27,28], arthritic pain [29], cerebral palsy with serious acute sialadenitis [29], and recently also in small-fiber neuropathy [30], trigeminal neuralgia [11,17,31] and refractory joint pain [18]. Presently, BoNT/A usage has been extended to many medical conditions, including in urological, gastroenterological, and surgical contexts [32]. BoNT/A is often used to reduce spasticity in a neurorehabilitation setting and to treat other disorders, including complex regional pain syndrome with focal dystonia and phantom limb [12,13]. Many papers suggest that the use of BoNT/A represents a novel therapeutic strategy, especially for neuropathic pain, whenever widely used pharmacological agents have been ineffective [29,30,33]. Animal studies, including ours, support the clinical observations [31,34–39]. Interestingly, BoNT/A also increases morphine-induced analgesia and prevents the development of morphine tolerance upon long-term treatment [40,41]. Despite its wide application in medicine, its mechanisms of action are still not fully understood. Several lines of evidence indicate the crucial role of neuron–glia interactions in the development and progression of neuropathic pain. Since an analgesic action of BoNT/A has been demonstrated, the question concerning the role of this toxin in the modulation of neuron–glia interactions arises. This review addresses the effects of BoNT/A on the relationship between glial and neuronal cells in treating neuropathic pain.

2. Mechanism-Based Evidence for the Analgesic Actions of Bont/A

The peripheral sensory neurons conduct nociceptive information, which enters the spinal cord dorsal horn and then from the spinal projection is conveyed to supraspinal structures (such as the brainstem, thalamus, somatosensory cortex, insular cortex and anterior cingulate cortex) via ascending pathways. Nerve injury form pre- and postsynaptic long-term plasticity within the brain structures, which contributes to emotional and motivational aspects of neuropathic pain condition. Studies using human brain imaging and genetically modified mice have shown that neuropathy is largely due to long-term plastic changes within the sensory pathways [42,43]. In the nervous system, neuronal activity is mediated by synaptic release of neurotransmitters. Under resting conditions, synaptic vesicles are delivered to plasma membrane and may undergo constitutive exocytosis after fusion with newly synthesized proteins in the membrane without uniquely identifiable regulators [44–46]. In contrast to constitutive the regulated exocytosis is under the strict control of calcium signals present only in activated neurons experiencing a rise in calcium concentration. During this process, the probability of vesicle fusion rises dramatically by increasement of cytosolic

calcium level, which is caused by the opening of voltage-gated calcium channels in response to the presence of an action potential at a nerve terminal [19,47,48]. In vivo studies showed that fast-regulated exocytosis requires the interaction of a members of protein superfamily, called SNAREs (soluble *N*-ethylmaleimide-sensitive factor attachment protein receptors), which are small cytoplasmically exposed membrane proteins. In regulated exocytosis, relevant SNAREs include synaptobrevin/VAMP (located on the membrane of the vesicle) and syntaxin-1 and SNAP-25 and/or its analogue SNAP-23 (localized on the plasma membrane), which create a complex representing the minimal mechanism required for fusion [49]. Increased calcium concentration (caused by calcium influx through voltage-gated calcium channels), is detected by synaptotagmin, and triggers fusion of docked synaptic vesicles, resulting in neurotransmitter release. Fusion is driven by a progressive zippering of vesicle and SNAREs proteins to form a strong four-helix bundle. Thus, the assembly of a SNARE complex represents crucial steps for nociceptive transmission between neuronal cells in the presence of neuropathic pain. Blockage of synaptic neurotransmission is strictly due to an inhibition of neurotransmitter release via vesicle-regulated exocytosis, and BoNT/A represents a powerful tool for the investigation of the involvement of SNAREs in exocytosis [35,50].

The involvement of BoNT/A in pain modulation mechanisms was first described by Cui et al., 2004 [51], who studied the effects of this toxin in inflammatory pain caused by formalin administration. Acting via SNAP-25, BoNT/A strongly inhibits the neuronal release of neurotransmitters and neuropeptides involved in nociceptive transmission, such as glutamate [51], substance P [20] and CGRP [21,52]. The authors demonstrated that single subcutaneous administration of BoNT/A into the paw after formalin injection reduced paw swelling and hypersensitivity to pain, and this effect was associated with inhibition of pronociceptive factors. In 2006, Luvisetto et al. [53], using a murine model of inflammatory pain, demonstrated that BoNT/A may act not only on the peripheral but also on the central nervous system (CNS). The analgesic effect of BoNT/A was also demonstrated in other inflammatory pain models, such as administration of carrageenan and capsaicin into the paw [34]. The authors suggested that intraarticular administration of BoNT/A is a promising method for the treatment of arthritis. The effects of BoNT/A were also studied in visceral pain models; it was also shown that intravenous administration of BoNT/A caused analgesia in an acetic acid-induced bladder pain model in rats [54]. In 2008, Antonucci et al. [55] suggested that the effects of BoNT/A might be due to retrograde transport or to the effect of transcytosis. Beneficial effects of BoNT/A were also observed in numerous clinical studies under neuropathic pain [11–18,30,31,38,39,56,57]. Several studies, including those conducted by our group, have shown that intraplantar injections of BoNT/A are also effective for treating neuropathic pain [31,35,36,38,40,58]. The results showed that BoNT/A diminished neuropathic pain by suppressing the secretion of neurotransmitters from neurons. Interesting results were obtained by the group of Vacca [40,41], who showed that administration of BoNT/A increased morphine antinociceptive action and countered morphine-induced tolerance after chronic treatment. These data suggest that BoNT/A is not only a potent analgesic but might also be useful as a component of multimodal pain therapy.

Attention has been paid to older works showing that radiolabeled BoNT/A injected into the cat gastrocnemius muscle is detected in the spine 24–38 h after administration [59,60]. Antonucci et al. [55] suggested retrograde transport and transcytosis as a mechanism by which BoNT/A acts not only at the administration site but also at the distant areas that project to the infusion region. In 2012, Marinelli et al. [61] used a murine model of neuropathy to demonstrate that BoNT/A injected intraplantarly may migrate from the site of administration into the sciatic nerve, DRG and spinal cord. Evidenced provided by Cui et al. [51] showed that analgesic BoNT/A action is correlated with modulation of central sensitization process, while BoNT/A has no impact on acute pain. Proposed mechanism of BoNT/A action is that toxin inhibits the release of neurotransmitters from peripheral nerve endings and reduces peripheral sensitization. Following this process, the afferent input to the spinal cord is damped and central sensitization is reduced, which suggest indirectly role of BoNT/A in this process. However, direct mechanism is also possible, as it was already shown that BoNT/A might be transported via retrograde

transport along the nociceptive neurons [55]. Based on those hypotheses, peripherally applied BoNT/A gains access to CNS and directly inhibits neurotransmitters release onto dorsal horn neurons.

In a 2016 paper by Zychowska et al. [39], intraplantar injections of BoNT/A not only relieved neuropathic pain-related behaviours but also restored the neuroimmune balance disturbed after nerve injury. BoNT/A diminished CCI-induced level of IL-1 β and IL-18 within the spinal cord and/or the DRG, and in parallel, it enhanced the levels of the anti-nociceptive interleukins IL-1RA and IL-10. Obtained data suggest that BoNT/A, in addition to altering neuronal function, can also influence spinal microglial cells [38,39]; however, it is still unclear whether those BoNT/A actions are mediated in a direct or indirect manner. The latest in vitro research by Piotrowska et al. 2017 [62] shed new light on the analgesic effect of BoNT/A and suggested a possible direct impact of this toxin on microglia in the CNS (Figure 1).




Figure 1. Suggested mechanism of botulinum toxin type A action under neuropathic pain conditions. (A) Intrathecal (*i.th.*) as well as intraplantar (*i.pl.*) injections of BoNT/A relief pain in animal models of neuropathy. Recent evidence suggests the possible retrograde transport and transcytosis of BoNT/A, which might be at least partially responsible for its analgesic effect. (B) Peripheral administration of BoNT/A reduced spinal microglial, but not astroglial, activation after sciatic nerve injury. (C,D) The data obtained from in vitro studies revealed that BoNT/A can directly influence microglial cells and it is achieved through the modulation of TLR2 receptor, SNARE proteins and intracellular pathways in microglial cells. BoNT/A diminishes LPS-induced phosphorylation of p38, ERK1/2, and NF- κ B and reduces the release of pro-inflammatory factors, such as IL-1 β , IL-18, IL-6, and anti-inflammatory IL-10 in microglia. No effects of BoNT/A on astroglia were observed. Mechanism of BoNT/A in glial cells is related to activation of TLRs, type 2 and 4. Complete activation of TLR2 in astroglia requires the presence of the microglial TLR4 receptor. Glial cross-talk may explain the lack of effect of BoNT/A on astroglia and it was suggested that the molecular target of BoNT/A is TLR2. See detailed description in the text **Abbreviations:** SNAP, synaptosomal-associated protein; TLR, Toll-like receptor; MyD, myeloid differentiation primary response gene; ERK1/2, extracellular-signal-regulated kinase 1/2; NF- κ B, nuclear factor- κ B; NOS2, inducible nitric oxide synthase; IL, interleukin; LPS, lipopolysaccharide, BoNT/A, botulinum toxin serotype A.

3. Far Beyond the Neurons—The Role of Glial Cells in Bont/A-Induced Analgesia

BoNT/A affects both SNAP-25 and -23 in neuronal cells; however, it was recently suggested that BoNT/A is also able to cleave SNAPs in astroglia and microglia [63,64]. Within the CNS, glial cells seem to play a crucial role in neuronal homeostasis [2,4,65,66]. Two main types of glial cells are present: macroglia (which include astroglia, oligodendrocytes and radial cells, including Bergmann and Müller cells) and microglia. Under physiological conditions, glial cells account for 70% of cells, and resting microglia account for only 5–20% of cells [3]. It is now obvious that glial cells are an important component of neural tissue and play a crucial role in the synthesis, release and uptake of many factors. The contribution of astroglia and microglia in the progression of neuropathy is well known [67,68]; however, the role of other macroglial cells (oligodendrocytes and radial cells) is still not well established. Under neuropathic pain, activated astroglia and microglia play a role in synaptic transmission based on the presence of similar receptors, ion channels, transporters and intracellular signaling cascades to neurons [66,68]. Glial cells are also capable of conducting active communication with neighboring neurons by gap junctions [69–71] and synapses [72–74].

Astroglia represent the most abundant cell population in the nervous system and are critical in maintaining the homeostasis of their surrounding environment by regulating the concentrations of the neurotransmitters, ions, and proteins in the synaptic cleft. Activation of astroglia as a result of peripheral neuropathy occurs approximately four days after microglial activation and persists until 12 weeks or longer after the injury, thus suggesting that astroglia are involved in the persistence of pain [68,75,76]. The direct influence of BoNT/A on astroglia was unclear, since the study by Parpura et al. (1995) [64] showed the expression of some of the SNARE protein complexes but not that of SNAP-25. The authors analyzed post-nuclear astroglial cell membrane extract, not the whole lysates as in Piotrowska et al. 2017 [62]. The authors, using *in vitro* primary cell culture studies, have demonstrated that astroglial cells possess both mRNA and protein for the SNAREs SNAP-25 and SNAP-23 [62]. These data correlate well with the study of Marinelli et al. (2012) [61] showing that BoNT/A exerts analgesic effects on neuropathic pain through the cleavage of SNAP-25 in spinal astroglia. Interestingly, *in vitro* studies gave evidence that BoNT/A did not influence pro-nociceptive factors (IL-1 β , IL-6, IL-18, and NOS2) or anti-nociceptive factors (IL-1RA, IL-10, and IL-18BP) in LPS-stimulated astroglial cell cultures [62] (Figure 1). The authors revealed that BoNT/A does not affect the activation of MAPKs, p38 and ERK1/2, or NF- κ B pathways in LPS-treated primary astroglial cell cultures. Moreover, they showed no changes in TLR2 and TLR4 expression, the adaptors for which initiate the activation of NF- κ B and MAPK cascades in astroglia, which is required for the production of nociceptive factors [77]. Surprisingly, BoNT/A appears to have no more than a slight direct effect on astroglia.

Recently, some authors have suggested that the molecular mechanism of BoNT/A action involves microglia [38,41]. Microglial cells are highly dynamic immune cells, which are responsible for the maintenance of homeostasis in the CNS [66,78]. They are known to dynamically modulate neuronal functions under neuropathic pain. They are the first cell type to become spinally activated following peripheral nerve injury [76] and remain active for several weeks [66,79–81]. Several reports have provided evidence that inhibitors of microglial activation, such as minocycline, propentofylline, and pentoxifylline, might largely limit the development of neuropathic pain [38,51,78,82–84] and those effects are due to reduced activation of microglial cells, which entails the inhibition of numerous cytokine secretion [85–87]. In 2011, Mika et al. [38] showed that a single intraplantar administration of BoNT/A, after nerve injury, attenuated neuropathic pain-related behaviors in neuropathic rats and, in parallel, reduced spinal microglial activation. The results provide evidence that BoNT/A, in addition to having an impact on neuronal functions, can also influence the activation of microglia; therefore, the involvement of these non-neuronal cells in BoNT/A action should also be regarded. Although *in vivo* studies have shown that BoNT/A influences the activation of microglial cells in rat and mouse neuropathic pain models [38,41], it was not clear if that occurred in a direct or indirect manner. The well-characterized molecular targets of BoNT/A action are superfamily of SNARE proteins.

The studies of Hepp et al. 1999 [63] suggested that in microglia, SNAP-25 is replaced by SNAP-23. SNAP-23 is structurally and functionally similar to SNAP-25 and binds tightly to multiple syntaxins and synaptobrevins/VAMPs. It is a crucial component of the high-affinity receptor for the general membrane fusion machinery and is an important regulator of transport vesicle docking and fusion. In 2017, Piotrowska et al. [62] using in vitro primary cell culture, demonstrated the presence of both mRNA and protein for SNAP-23, but not for SNAP-25, in microglia. The in vitro studies correspond well with in vivo data obtained by Marinelli et al. (2012) [61], where the authors did not observe staining for cleaved SNAP-25 protein co-localized with microglia. Therefore, it seems that SNAP-23, not SNAP-25, plays an important role in the effects of BoNT/A on microglia.

Zychowska et al. (2016) [39] showed that BoNT/A injection reverts the neuro-immune changes after sciatic nerve injury. In vitro studies with glial cell cultures [62] revealed the inhibitory action of BoNT/A on the intracellular cascades, which is possibly involved in changes in the expression of many nociceptive factors. BoNT/A prevents the LPS-induced upregulation of pro-nociceptive factors (IL-1 β , IL-18, NOS2) through the modulation of intracellular pathways activation (NF- κ B, p38 and ERK1/2) and increases the expression of TLR2 and its adaptor protein MyD88 in microglia (Figure 1). These results can be compared with those published in 2015 by Kim et al. [88] who showed that BoNT/A inhibited LPS-upregulated NO production in RAW264.7 macrophages by blocking the activation of ERK and p38.

Recently, many papers have shown that the inhibition of the MAPK family members (namely p38 and ERK1/2) leads to lower rates of neuropathy in animal models, down-regulated pro-nociceptive factors and enhanced opioid efficiency [84,89–96]. The in vitro results of Piotrowska et al. (2017) have shown that BoNT/A decreased the LPS-induced activation of p38 and ERK1/2 in microglia; similar results were obtained in the monocyte/macrophage cell line RAW264.7 by Kim et al. (2015) [88]. Many studies have shown an important role for the NF- κ B pathway in nociception and microglial cell activation [94–99]. In vitro results of Piotrowska et al. (2017) [62] revealed that BoNT/A reduced NF- κ B phosphorylation in LPS-treated microglia. It has been shown that the inhibition of NF- κ B with a potent inhibitor, parthenolide, diminished the symptoms of neuropathic pain, and, moreover, it potentiated morphine-induced analgesia and reduced the levels of pro-nociceptive factors produced by microglial cells (such as IL-1 β , IL-18, NOS2) [95].

Among the numerous receptors expressed by microglial cells, the family of TLR receptors, especially subtypes 2 and 4, represents a possible link between microglia activation and nerve injury and illustrate an essential role of those cells in the development of neuropathy [100–103]. The TLRs are a type of receptor, which are important for pathogen recognition. Activation of those receptors leads to the initiation of direct antimicrobial pathways, expression of co-stimulatory factors, and release of cytokines via NF- κ B and/or MAPK signaling pathways. The TLRs family recognize pathogen-associated molecular patterns (PAMPs), expression of which is characteristic for infectious agents [104,105]. The TLRs can also discern danger-associated molecular patterns (DAMPs), products of nerve injury [106]. It has been confirmed that TLR2 or TLR4 knockout mice have less microglial activation after nerve injury and fewer neuropathic pain symptoms [100,101,103,107]. Piotrowska et al. (2017) [62] revealed that LPS induced a decrease in TLR4 in microglia. Recently, studies using macrophages revealed that BoNT/A is sensed by TLR2, but not by TLR4 [88]. In turn, BoNT/A increased the TLR2 level in LPS-stimulated microglia. It has been demonstrated that TLR4 activation is mediated by dimerization of adaptor proteins (MyD88 or TRIF), but TLR2 uses only MyD88 [108]. Our data have proven that BoNT/A administration rescues downregulated by LPS level of MyD88 in microglia [62]. Recently, an interaction between TLR signaling and SNARE proteins has been suggested. In 2014, Nair-Gupta et al. [109] showed that MyD88-dependent TLR signaling is involved in the phosphorylation of SNAP-23 present on the phagosome in dendritic cells. The phosphorylated SNAP-23 protein stabilizes SNARE complexes, which leads to fusion with the endosomal recycling compartment and ultimately to cross-presentation. In our opinion, we observed a similar phenomenon in microglia: these cells act as key players in the immune response

in the CNS. Microglia are the resident innate immune cells and within CNS they are responsible for the early control of infections and for the recruitment of cells of the adaptive immune system, which are required for pathogen clearance [110]. Thus, it seems that the microglial TLR/MyD88/NF- κ B cascade contributes to the decrease of SNAP-23. Recently, it has been suggested that microglia are characterized by heightened expression of TLRs and by a stronger response to LPS compared to astroglia [111]. Furthermore, in 2012 Holm et al. [111] discovered that the response of astroglial cells to TLR2 agonists is completely dependent on the presence of functional TLR4 in microglial cells. The activation of TLR4 by LPS induces a synthesis of closely related TLR2 [112]. In 2017, Piotrowska et al. [62] did not observe changes in expression of the analyzed factors, with the exception of SNAP-23 and SNAP-25, after BoNT/A treatment in LPS-stimulated astroglia. The authors suggested that TLR2 is another important molecular target for BoNT/A. In sum, BoNT/A exerts its anti-inflammatory action by inhibiting signaling pathways (such as NF- κ B, p38 and ERK1/2) activation in microglia; very importantly, it can directly interact with TLR2. Based on the current state of knowledge, we can hypothesize that the full activation of astroglial TLR2 requires the presence of functional TLR4 in microglia, which emphasizes the significant cross-talk between those cells types within the CNS.

4. Conclusions

Further investigation concerning the action of BoNT/A in the CNS is needed and will provide priceless information to help understand the pathophysiology of neuropathic pain. The literature provides evidence that BoNT/A, in addition to having an impact on neuronal functions, can also influence the activation of microglia; therefore, the involvement of these non-neuronal cells in the BoNT/A mechanism of action should also be regarded as an important component of its analgesic effects. However, BoNT/A appears to have no more than a slight direct effect on astroglia. In our opinion, BoNT/A is a powerful modulator of neuron–glia interactions in the CNS in the context of neuropathic pain. More research into BoNT/A as a treatment for neuropathy is warranted because it could be an attractive alternative for patients who do not respond positively to other drugs.

Acknowledgments: This work was supported by the National Science Centre, Poland grant HARMONIA 5 2013/10/M/NZ4/00261, and statutory funds of the Institute of Pharmacology Polish Academy of Sciences. The English language in the manuscript was edited by American Journal Experts.

Author Contributions: E.R., A.P., K.P.-B. and J.M. made substantial contributions to the conception and design of the study, and were involved in drafting the manuscript or revising it critically. All authors made substantial contributions to the acquisition and interpretation of data and have given final approval of the version for publication.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Austin, P.J.; Moalem-Taylor, G. The neuro-immune balance in neuropathic pain: Involvement of inflammatory immune cells, immune-like glial cells and cytokines. *J. Neuroimmunol.* **2010**, *229*, 26–50. [[CrossRef](#)] [[PubMed](#)]
2. Mika, J.; Zychowska, M.; Popiolek-Barczyk, K.; Rojewska, E.; Przewlocka, B. Importance of glial activation in neuropathic pain. *Eur. J. Pharmacol.* **2013**, *716*, 106–119. [[CrossRef](#)] [[PubMed](#)]
3. Watkins, L.R.; Milligan, E.D.; Maier, S.F. Glial activation: A driving force for pathological pain. *Trends Neurosci.* **2001**, *24*, 450–455. [[CrossRef](#)]
4. Watkins, L.R.; Maier, S.F. GLIA: A novel drug discovery target for clinical pain. *Nat. Rev. Drug Discov.* **2003**, *2*, 973–985. [[CrossRef](#)] [[PubMed](#)]
5. Gibson, W.; Wand, B.M.; O’Connell, N.E. Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults. *Cochrane Database Syst. Rev.* **2017**, *2017*, CD011976. [[CrossRef](#)] [[PubMed](#)]
6. Hatch, M.N.; Cushing, T.R.; Carlson, G.D.; Chang, E.Y. Neuropathic pain and SCI: Identification and treatment strategies in the 21st century. *J. Neurol. Sci.* **2017**, *384*, 75–83. [[CrossRef](#)] [[PubMed](#)]
7. Çakici, N.; Fakkal, T.M.; van Neck, J.W.; Verhagen, A.P.; Coert, J.H. Systematic review of treatments for diabetic peripheral neuropathy. *Diabet. Med.* **2016**, *33*, 1466–1476. [[CrossRef](#)] [[PubMed](#)]

8. Tamburin, S.; Lacerenza, M.R.; Castelnuovo, G.; Agostini, M.; Paolucci, S.; Bartolo, M.; Bonazza, S.; Federico, A.; Formaglio, F.; Giusti, E.M.; et al. Italian Consensus Conference on Pain in Neurorehabilitation (ICCPN) Pharmacological and non-pharmacological strategies in the integrated treatment of pain in neurorehabilitation. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. *Eur. J. Phys. Rehabil. Med.* **2016**, *52*, 741–752. [[PubMed](#)]
9. Boldt, I.; Eriks-Hoogland, I.; Brinkhof, M.W.G.; de Bie, R.; Joggi, D.; von Elm, E. Non-pharmacological interventions for chronic pain in people with spinal cord injury. *Cochrane Database Syst. Rev.* **2014**, *11*, CD009177. [[CrossRef](#)] [[PubMed](#)]
10. Johnson, E.A. Clostridial toxins as therapeutic agents: Benefits of nature's most toxic proteins. *Annu. Rev. Microbiol.* **1999**, *53*, 551–575. [[CrossRef](#)] [[PubMed](#)]
11. Castillo-Álvarez, F.; Hernando de la Bárcena, I.; Marzo-Sola, M.E. Botulinum toxin in trigeminal neuralgia. *Med. Clin. (Barc)* **2017**, *148*, 28–32. [[CrossRef](#)] [[PubMed](#)]
12. Alviar, M.J.M.; Hale, T.; Dungca, M. Pharmacologic interventions for treating phantom limb pain. *Cochrane Database Syst. Rev.* **2016**, *10*, CD006380. [[CrossRef](#)] [[PubMed](#)]
13. Bruno, V.A.; Fox, S.H.; Mancini, D.; Miyasaki, J.M. Botulinum Toxin Use in Refractory Pain and Other Symptoms in Parkinsonism. *Can. J. Neurol. Sci.* **2016**, *43*, 697–702. [[CrossRef](#)] [[PubMed](#)]
14. Cho, S.-J.; Song, T.-J.; Chu, M.K. Treatment Update of Chronic Migraine. *Curr. Pain Headache Rep.* **2017**, *21*, 26. [[CrossRef](#)] [[PubMed](#)]
15. Cuadrado, M.L.; García-Moreno, H.; Arias, J.A.; Pareja, J.A. Botulinum neurotoxin type-A for the treatment of atypical odontalgia. *Pain Med.* **2016**, *17*, 1717–1721. [[CrossRef](#)] [[PubMed](#)]
16. Kleen, J.K.; Levin, M. Injection Therapy for Headache and Facial Pain. *Oral Maxillofac. Surg. Clin. N. Am.* **2016**, *28*, 423–434. [[CrossRef](#)] [[PubMed](#)]
17. Lunde, H.M.B.; Torkildsen, Ø.; Bø, L.; Bertelsen, A.K. Botulinum Toxin as Monotherapy in Symptomatic Trigeminal Neuralgia. *Headache* **2016**, *56*, 1035–1039. [[CrossRef](#)] [[PubMed](#)]
18. Wu, T.; Song, H.; Dong, Y.; Ye, Y.; Li, J. Intra-articular injections of botulinum toxin a for refractory joint pain: A systematic review and meta-analysis. *Clin. Rehabil.* **2017**, *31*, 435–443. [[CrossRef](#)] [[PubMed](#)]
19. Montecucco, C.; Molgó, J. Botulinum neurotoxins: Revival of an old killer. *Curr. Opin. Pharmacol.* **2005**, *5*, 274–279. [[CrossRef](#)] [[PubMed](#)]
20. Welch, M.J.; Purkiss, J.R.; Foster, K. A Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. *Toxicon* **2000**, *38*, 245–258. [[CrossRef](#)]
21. Durham, P.L.; Cady, R.; Cady, R.; Blumenfeld, A.J. Regulation of Calcitonin Gene-Related Peptide Secretion from Trigeminal Nerve Cells by Botulinum Toxin Type A: Implications for Migraine Therapy. *Headache* **2004**, *44*, 35–43. [[CrossRef](#)] [[PubMed](#)]
22. Krämer, H.H.; Angerer, C.; Erbguth, F.; Schmelz, M.; Birklein, F. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. *J. Neurol.* **2003**, *250*, 188–193. [[CrossRef](#)] [[PubMed](#)]
23. Burstein, R.; Zhang, X.C.; Levy, D.; Aoki, K.R.; Brin, M.F. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains. *Cephalalgia* **2014**, *34*, 853–869. [[CrossRef](#)] [[PubMed](#)]
24. Brodsky, M.A.; Swope, D.M.; Grimes, D. Diffusion of botulinum toxins. *Tremor Other Hyperkinet. Mov.* **2012**, *2*, 319–322. [[CrossRef](#)]
25. Klein, A.W. The therapeutic potential of botulinum toxin. *Dermatol. Surg.* **2004**, *30*, 452–455. [[PubMed](#)]
26. Wheeler, A.H. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. *Headache* **1998**, *38*, 468–471. [[CrossRef](#)] [[PubMed](#)]
27. Binder, W.J.; Brin, M.F.; Blitzler, A.; Schoenrock, L.D.; Pogoda, J.M. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study. *Otolaryngol. Head Neck Surg.* **2000**, *123*, 669–676. [[CrossRef](#)] [[PubMed](#)]
28. Ashkenazi, A. Botulinum toxin type a for chronic migraine. *Curr. Neurol. Neurosci. Rep.* **2010**, *10*, 140–146. [[CrossRef](#)] [[PubMed](#)]
29. Yuan, R.Y.; Sheu, J.J.; Yu, J.M.; Chen, W.T.; Tseng, I.J.; Chang, H.H.; Hu, C.J. Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial. *Neurology* **2009**, *72*, 1473–1478. [[CrossRef](#)] [[PubMed](#)]

30. Ranoux, D.; Attal, N.; Morain, F.; Bouhassira, D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. *Ann. Neurol.* **2008**, *64*, 274–283. [[CrossRef](#)] [[PubMed](#)]
31. Kitamura, Y.; Matsuka, Y.; Spigelman, I.; Ishihara, Y.; Yamamoto, Y.; Sonoyama, W.; Kuboki, T.; Oguma, K. Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. *Neuroscience* **2009**, *159*, 1422–1429. [[CrossRef](#)] [[PubMed](#)]
32. Arbizu, R.A.; Rodriguez, L. Use of Clostridium botulinum toxin in gastrointestinal motility disorders in children. *World J. Gastrointest. Endosc.* **2015**, *7*, 433–437. [[CrossRef](#)] [[PubMed](#)]
33. Intiso, D.; Basciani, M.; Santamato, A.; Intiso, M.; Di Rienzo, F. Botulinum toxin type a for the treatment of neuropathic pain in neuro-rehabilitation. *Toxins* **2015**, *7*, 2454–2480. [[CrossRef](#)] [[PubMed](#)]
34. Bach-Rojecky, L.; Lacković, Z. Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain. *Croat. Med. J.* **2005**, *46*, 201–208. [[PubMed](#)]
35. Luvisetto, S.; Rossetto, O.; Montecucco, C.; Pavone, F. Toxicity of botulinum neurotoxins in central nervous system of mice. *Toxicon* **2003**, *41*, 475–481. [[CrossRef](#)]
36. Luvisetto, S.; Marinelli, S.; Cobianchi, S.; Pavone, F. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. *Neuroscience* **2007**, *145*, 1–4. [[CrossRef](#)] [[PubMed](#)]
37. Marinelli, S.; Luvisetto, S.; Cobianchi, S.; Makuch, W.; Obara, I.; Mezzaroma, E.; Caruso, M.; Straface, E.; Przewlocka, B.; Pavone, F. Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. *Neuroscience* **2010**, *171*, 316–328. [[CrossRef](#)] [[PubMed](#)]
38. Mika, J.; Rojewska, E.; Makuch, W.; Korostynski, M.; Luvisetto, S.; Marinelli, S.; Pavone, F.; Przewlocka, B. The effect of botulinum neurotoxin A on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cord. *Neuroscience* **2011**, *175*, 358–366. [[CrossRef](#)] [[PubMed](#)]
39. Zychowska, M.; Rojewska, E.; Makuch, W.; Luvisetto, S.; Pavone, F.; Marinelli, S.; Przewlocka, B.; Mika, J. Participation of pro- and anti-nociceptive interleukins in botulinum toxin A-induced analgesia in a rat model of neuropathic pain. *Eur. J. Pharmacol.* **2016**, *791*, 377–388. [[CrossRef](#)] [[PubMed](#)]
40. Vacca, V.; Marinelli, S.; Eleuteri, C.; Luvisetto, S.; Pavone, F. Botulinum neurotoxin A enhances the analgesic effects on inflammatory pain and antagonizes tolerance induced by morphine in mice. *Brain Behav. Immun.* **2012**, *26*, 489–499. [[CrossRef](#)] [[PubMed](#)]
41. Vacca, V.; Marinelli, S.; Luvisetto, S.; Pavone, F. Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and μ opioid receptor expression in neuropathic mice. *Brain Behav. Immun.* **2013**, *32*, 40–50. [[CrossRef](#)] [[PubMed](#)]
42. Tsuda, M.; Koga, K.; Chen, T.; Zhuo, M. Neuronal and microglial mechanisms for neuropathic pain in the spinal dorsal horn and anterior cingulate cortex. *J. Neurochem.* **2017**, *141*, 486–498. [[CrossRef](#)] [[PubMed](#)]
43. Zhuo, M.; Wu, G.; Wu, L.J. Neuronal and microglial mechanisms of neuropathic pain. *Mol. Brain* **2011**, *4*, 31. [[CrossRef](#)] [[PubMed](#)]
44. Wasser, C.R.; Kavalali, E.T. Leaky synapses: Regulation of spontaneous neurotransmission in central synapses. *Neuroscience* **2009**, *158*, 177–188. [[CrossRef](#)] [[PubMed](#)]
45. Choi, B.J.; Imlach, W.L.; Jiao, W.; Wolfram, V.; Wu, Y.; Grbic, M.; Cela, C.; Baines, R.A.; Nitabach, M.N.; McCabe, B.D. Miniature Neurotransmission Regulates Drosophila Synaptic Structural Maturation. *Neuron* **2014**, *82*, 618–634. [[CrossRef](#)] [[PubMed](#)]
46. Molgó, J.; Siegel, L.S.; Tabti, N.; Thesleff, S. A study of synchronization of quantal transmitter release from mammalian motor endings by the use of botulin toxins type A and D. *J. Physiol.* **1989**, *411*, 195–205. [[CrossRef](#)] [[PubMed](#)]
47. Rossetto, O.; Seveso, M.; Caccin, P.; Schiavo, G.; Montecucco, C. Tetanus and botulinum neurotoxins: Turning bad guys into good by research. *Toxicon* **2001**, *39*, 27–41. [[CrossRef](#)]
48. Katz, E.; Ferro, P.A.; Cherksey, B.D.; Sugimori, M.; Llinas, R.; Uchitel, O.D. Effects of Ca²⁺ channel blockers on transmitter release and presynaptic currents at the frog neuromuscular junction. *J. Physiol.* **1995**, *486*, 695–706. [[CrossRef](#)] [[PubMed](#)]
49. Südhof, T.C.; Rothman, J.E. Membrane fusion: Grappling with SNARE and SM proteins. *Science* **2009**, *323*, 474–477. [[CrossRef](#)] [[PubMed](#)]
50. Pantano, S.; Montecucco, C. The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. *Cell. Mol. Life Sci.* **2014**, *71*, 793–811. [[CrossRef](#)] [[PubMed](#)]

51. Cui, M.; Khanijou, S.; Rubino, J.; Aoki, K.R. Subcutaneous administration of botulinum toxin a reduces formalin-induced pain. *Pain* **2004**, *107*, 125–133. [[CrossRef](#)] [[PubMed](#)]
52. Meng, J.; Wang, J.; Lawrence, G.; Dolly, J.O. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. *J. Cell Sci.* **2007**, *120*, 2864–2874. [[CrossRef](#)] [[PubMed](#)]
53. Luvisetto, S.; Marinelli, S.; Lucchetti, F.; Marchi, F.; Cobianchi, S.; Rossetto, O.; Montecucco, C.; Pavone, F. Botulinum neurotoxins and formalin-induced pain: Central vs. peripheral effects in mice. *Brain Res.* **2006**, *1082*, 124–131. [[CrossRef](#)] [[PubMed](#)]
54. Chuang, Y.C.; Yoshimura, N.; Huang, C.C.; Chiang, P.H.; Chancellor, M.B. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. *J. Urol.* **2004**, *172* (4 Pt 1), 1529–1532. [[CrossRef](#)] [[PubMed](#)]
55. Antonucci, F.; Rossi, C.; Gianfranceschi, L.; Rossetto, O.; Caleo, M. Long-Distance Retrograde Effects of Botulinum Neurotoxin A. *J. Neurosci.* **2008**, *28*, 3689–3696. [[CrossRef](#)] [[PubMed](#)]
56. Foster, K.A.; Bigalke, H.; Aoki, K.R. Botulinum neurotoxin—From laboratory to bedside. *Neurotox. Res.* **2006**, *9*, 133–140. [[CrossRef](#)] [[PubMed](#)]
57. Jabbari, B. Botulinum neurotoxins in the treatment of refractory pain. *Nat. Clin. Pract. Neurol.* **2008**, *4*, 676–685. [[CrossRef](#)] [[PubMed](#)]
58. Bach-Rojecky, L.; Relja, M.; Lacković, Z. Botulinum toxin type A in experimental neuropathic pain. *J. Neural Transm. Vienna Austria 1996* **2005**, *112*, 215–219. [[CrossRef](#)] [[PubMed](#)]
59. Habermann, E. 125I-labeled neurotoxin from clostridium botulinum A: Preparation, binding to synaptosomes and ascent to the spinal cord. *Naunyn Schmiedebergs Arch. Pharmacol.* **1974**, *281*, 47–56. [[CrossRef](#)] [[PubMed](#)]
60. Wiegand, H.; Erdmann, G.; Wellhöner, H.H. 125I-Labelled botulinum a neurotoxin: Pharmacokinetics in cats after intramuscular injection. *Naunyn. Schmiedebergs. Arch. Pharmacol.* **1976**, *292*, 161–165. [[CrossRef](#)] [[PubMed](#)]
61. Marinelli, S.; Vacca, V.; Ricordy, R.; Ugenti, C.; Tata, A.M.; Luvisetto, S.; Pavone, F. The Analgesic Effect on Neuropathic Pain of Retrogradely Transported botulinum Neurotoxin A Involves Schwann Cells and Astrocytes. *PLoS ONE* **2012**, *7*, e47977. [[CrossRef](#)] [[PubMed](#)]
62. Piotrowska, A.; Popiolek-Barczyk, K.; Pavone, F.; Mika, J. Comparison of the Expression Changes after Botulinum Toxin Type A and Minocycline Administration in Lipopolysaccharide-Stimulated Rat Microglial and Astroglial Cultures. *Front. Cell. Infect. Microbiol.* **2017**, *7*, 147. [[CrossRef](#)] [[PubMed](#)]
63. Hepp, R.; Perraut, M.; Chasserot-Golaz, S.; Galli, T.; Aunis, D.; Langley, K.; Grant, N.J. Cultured glial cells express the SNAP-25 analogue SNAP-23. *Glia* **1999**, *27*, 181–187. [[CrossRef](#)]
64. Parpura, V.; Fang, Y.; Basarsky, T.; Jahn, R.; Haydon, P.G. Expression of synaptobrevin II, cellubrevin and syntaxin but not SNAP-25 in cultured astrocytes. *FEBS Lett.* **1995**, *377*, 489–492. [[CrossRef](#)] [[PubMed](#)]
65. DeLeo, J.A.; Yeziarski, R.P. The role of neuroinflammation and neuroimmune activation in persistent pain. *Pain* **2001**, *90*, 1–6. [[CrossRef](#)]
66. Popiolek-Barczyk, K.; Mika, J. Targeting the microglial signaling pathways: New insights in the modulation of neuropathic pain. *Curr. Med. Chem.* **2016**, *23*, 2908–2928. [[CrossRef](#)] [[PubMed](#)]
67. Colburn, R.W.; DeLeo, J.A.; Rickman, A.J.; Yeager, M.P.; Kwon, P.; Hickey, W.F. Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat. *J. Neuroimmunol.* **1997**, *79*, 163–175. [[CrossRef](#)]
68. Colburn, R.W.; Rickman, A.J.; Deleo, J.A. The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior. *Exp. Neurol.* **1999**, *157*, 289–304. [[CrossRef](#)] [[PubMed](#)]
69. Nedergaard, M. Direct signaling from astrocytes to neurons in cultures of mammalian brain cells. *Science* **1994**, *263*, 1768–1771. [[CrossRef](#)] [[PubMed](#)]
70. Roh, D.H.; Yoon, S.Y.; Seo, H.S.; Kang, S.Y.; Han, H.J.; Beitz, A.J.; Lee, J.H. Intrathecal injection of carbenoxolone, a gap junction decoupler, attenuates the induction of below-level neuropathic pain after spinal cord injury in rats. *Exp. Neurol.* **2010**, *224*, 123–132. [[CrossRef](#)] [[PubMed](#)]
71. Zündorf, G.; Kahlert, S.; Reiser, G. Gap-junction blocker carbenoxolone differentially enhances NMDA-induced cell death in hippocampal neurons and astrocytes in co-culture. *J. Neurochem.* **2007**, *102*, 508–521. [[CrossRef](#)] [[PubMed](#)]
72. Haber, M.; Murai, K.K. Reshaping neuron-glia communication at hippocampal synapses. *Neuron Glia Biol.* **2006**, *2*, 59–66. [[CrossRef](#)] [[PubMed](#)]

73. Panatier, A.; Vallée, J.; Haber, M.; Murai, K.K.; Lacaille, J.C.; Robitaille, R. Astrocytes are endogenous regulators of basal transmission at central synapses. *Cell* **2011**, *146*, 785–798. [[CrossRef](#)] [[PubMed](#)]
74. Oliet, S.H.R.; Panatier, A.; Piet, R.; Mothet, J.P.; Poulain, D.A.; Theodosis, D.T. Neuron-glia interactions in the rat supraoptic nucleus. *Prog. Brain Res.* **2008**, *170*, 109–117. [[PubMed](#)]
75. Romero-Sandoval, A.; Chai, N.; Natile-McMenemy, N.; DeLeo, J.A. A comparison of spinal Iba1 and GFAP expression in rodent models of acute and chronic pain. *Brain Res.* **2008**, *1219*, 116–126. [[CrossRef](#)] [[PubMed](#)]
76. Tanga, F.Y.; Raghavendra, V.; DeLeo, J.A. Quantitative real-time RT-PCR assessment of spinal microglial and astrocytic activation markers in a rat model of neuropathic pain. *Neurochem. Int.* **2004**, *45*, 397–407. [[CrossRef](#)] [[PubMed](#)]
77. Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: Update on toll-like receptors. *Nat. Immunol.* **2010**, *11*, 373–384. [[CrossRef](#)] [[PubMed](#)]
78. Mika, J. Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. *Pharmacol. Rep.* **2008**, *60*, 297–307. [[PubMed](#)]
79. Clark, A.K.; Gentry, C.; Bradbury, E.J.; McMahon, S.B.; Malcangio, M. Role of spinal microglia in rat models of peripheral nerve injury and inflammation. *Eur. J. Pain* **2007**, *11*, 223–230. [[CrossRef](#)] [[PubMed](#)]
80. Coyle, D.E. Partial peripheral nerve injury leads to activation of astroglia and microglia which parallels the development of allodynic behavior. *Glia* **1998**, *23*, 75–83. [[CrossRef](#)]
81. Zychowska, M.; Rojewska, E.; Przewlocka, B.; Mika, J. Mechanisms and pharmacology of diabetic neuropathy—Experimental and clinical studies. *Pharmacol. Rep.* **2013**, *65*, 1601–1610. [[CrossRef](#)]
82. Amin, A.R.; Attur, M.G.; Thakker, G.D.; Patel, P.D.; Vyas, P.R.; Patel, R.N.; Patel, I.R.; Abramson, S.B. A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 14014–14019. [[CrossRef](#)] [[PubMed](#)]
83. Colovic, M.; Caccia, S. Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. *J. Chromatogr. A* **2003**, *791*, 337–343. [[CrossRef](#)]
84. Mika, J.; Osikowicz, M.; Rojewska, E.; Korostynski, M.; Wawrzczak-Bargiela, A.; Przewlocki, R.; Przewlocka, B. Differential activation of spinal microglial and astroglial cells in a mouse model of peripheral neuropathic pain. *Eur. J. Pharmacol.* **2009**, *623*, 65–72. [[CrossRef](#)] [[PubMed](#)]
85. Lundblad, R.; Ekstrøm, P.; Giercksky, K.E. Pentoxifylline improves survival and reduces tumor necrosis factor, interleukin-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats. *Shock* **1995**, *3*, 210–215. [[CrossRef](#)] [[PubMed](#)]
86. Mika, J.; Osikowicz, M.; Makuch, W.; Przewlocka, B. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. *Eur. J. Pharmacol.* **2007**, *560*, 142–149. [[CrossRef](#)] [[PubMed](#)]
87. Sweitzer, S.M.; Schubert, P.; DeLeo, J.A. Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain. *J. Pharmacol. Exp. Ther.* **2001**, *297*, 1210–1217. [[PubMed](#)]
88. Kim, Y.J.; Kim, J.-H.; Lee, K.-J.; Choi, M.-M.; Kim, Y.H.; Rhie, G.; Yoo, C.-K.; Cha, K.; Shin, N.-R. Botulinum Neurotoxin Type A Induces TLR2-Mediated Inflammatory Responses in Macrophages. *PLoS ONE* **2015**, *10*, e0120840. [[CrossRef](#)] [[PubMed](#)]
89. Jin, S.X.; Zhuang, Z.Y.; Woolf, C.J.; Ji, R.R. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. *J. Neurosci.* **2003**, *23*, 4017–4022. [[PubMed](#)]
90. Tsuda, M.; Mizokoshi, A.; Shigemoto-Mogami, Y.; Koizumi, S.; Inoue, K. Activation of p38 Mitogen-Activated Protein Kinase in Spinal Hyperactive Microglia Contributes to Pain Hypersensitivity Following Peripheral Nerve Injury. *Glia* **2004**, *45*, 89–95. [[CrossRef](#)] [[PubMed](#)]
91. Ma, W.; Quirion, R. The ERK/MAPK pathway, as a target for the treatment of neuropathic pain. *Expert Opin. Ther. Targets* **2005**, *9*, 699–713. [[CrossRef](#)] [[PubMed](#)]
92. Rojewska, E.; Popiolek-Barczyk, K.; Jurga, A.M.; Makuch, W.; Przewlocka, B.; Mika, J. Involvement of pro- and antinociceptive factors in minocycline analgesia in rat neuropathic pain model. *J. Neuroimmunol.* **2014**, *277*, 57–66. [[CrossRef](#)] [[PubMed](#)]
93. Rojewska, E.; Piotrowska, A.; Makuch, W.; Przewlocka, B.; Mika, J. Pharmacological kynurenine 3-monooxygenase enzyme inhibition significantly reduces neuropathic pain in a rat model. *Neuropharmacology* **2016**, *102*, 80–91. [[CrossRef](#)] [[PubMed](#)]

94. Mika, J.; Popiolek-Barczyk, K.; Rojewska, E.; Makuch, W.; Starowicz, K.; Przewlocka, B. Delta-opioid receptor analgesia is independent of microglial activation in a rat model of neuropathic pain. *PLoS ONE* **2014**, *9*, e104420. [[CrossRef](#)] [[PubMed](#)]
95. Popiolek-Barczyk, K.; Kolosowska, N.; Piotrowska, A.; Makuch, W.; Rojewska, E.; Jurga, A.M.; Pilat, D.; Mika, J. Parthenolide relieves pain and promotes M2 microglia/macrophage polarization in rat model of neuropathy. *Neural Plast.* **2015**, *2015*. [[CrossRef](#)] [[PubMed](#)]
96. Piotrowska, A.; Kwiatkowski, K.; Rojewska, E.; Makuch, W.; Mika, J. Maraviroc reduces neuropathic pain through polarization of microglia and astroglia—Evidence from in vivo and in vitro studies. *Neuropharmacology* **2016**, *108*, 207–219. [[CrossRef](#)] [[PubMed](#)]
97. Ma, W.; Bisby, M. a Increased activation of nuclear factor kappa B in rat lumbar dorsal root ganglion neurons following partial sciatic nerve injuries. *Brain Res.* **1998**, *797*, 243–254. [[CrossRef](#)]
98. Meunier, A.; Latrémolière, A.; Dominguez, E.; Mauborgne, A.; Philippe, S.; Hamon, M.; Mallet, J.; Benoliel, J.J.; Pohl, M. Lentiviral-mediated targeted NF- κ B blockade in dorsal spinal cord glia attenuates sciatic nerve injury-induced neuropathic pain in the rat. *Mol. Ther.* **2007**, *15*, 687–697. [[CrossRef](#)] [[PubMed](#)]
99. Miyoshi, K.; Obata, K.; Kondo, T.; Okamura, H.; Noguchi, K. Interleukin-18-Mediated Microglia/Astrocyte Interaction in the Spinal Cord Enhances Neuropathic Pain Processing after Nerve Injury. *J. Neurosci.* **2008**, *28*, 12775–12787. [[CrossRef](#)] [[PubMed](#)]
100. Jurga, A.M.; Rojewska, E.; Piotrowska, A.; Makuch, W.; Pilat, D.; Przewlocka, B.; Mika, J. Blockade of toll-like receptors (TLR2, TLR4) attenuates pain and potentiates buprenorphine analgesia in a rat neuropathic pain model. *Neural Plast.* **2016**, *2016*. [[CrossRef](#)] [[PubMed](#)]
101. Kim, D.; Kim, M.A.; Cho, I.-H.; Kim, M.S.; Lee, S.; Jo, E.-K.; Choi, S.-Y.; Park, K.; Kim, J.S.; Akira, S.; et al. A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity. *J. Biol. Chem.* **2007**, *282*, 14975–14983. [[CrossRef](#)] [[PubMed](#)]
102. Lehnardt, S.; Massillon, L.; Follett, P.; Jensen, F.E.; Ratan, R.; Rosenberg, P.A.; Volpe, J.J.; Vartanian, T. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 8514–8519. [[CrossRef](#)] [[PubMed](#)]
103. Tanga, F.Y.; Nutile-McMenemy, N.; DeLeo, J.A. The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 5856–5861. [[CrossRef](#)] [[PubMed](#)]
104. Borrello, S.; Nicolò, C.; Delogu, G.; Pandolfi, F.; Ria, F. TLR2: A crossroads between infections and autoimmunity? *Int. J. Immunopathol. Pharmacol.* **2011**, *24*, 549–556. [[CrossRef](#)] [[PubMed](#)]
105. Medzhitov, R.; Preston-Hurlburt, P.; Janeway, C.A. A human homologue of the Drosophila toll protein signals activation of adaptive immunity. *Nature* **1997**, *388*, 394–397. [[CrossRef](#)] [[PubMed](#)]
106. Liu, T.; Gao, Y.-J.; Ji, R.-R. Emerging role of Toll-like receptors in the control of pain and itch. *Neurosci. Bull.* **2012**, *28*, 131–144. [[CrossRef](#)] [[PubMed](#)]
107. Miyake, K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. *Semin. Immunol.* **2007**, *19*, 3–10. [[CrossRef](#)] [[PubMed](#)]
108. Kigerl, K.A.; de Rivero Vaccari, J.P.; Dietrich, W.D.; Popovich, P.G.; Keane, R.W. Pattern recognition receptors and central nervous system repair. *Exp. Neurol.* **2014**, *258*, 5–16. [[CrossRef](#)] [[PubMed](#)]
109. Nair-Gupta, P.; Baccarini, A.; Tung, N.; Seyffer, F.; Florey, O.; Huang, Y.; Banerjee, M.; Overholtzer, M.; Roche, P.A.; Tampé, R.; et al. TLR signals induce phagosomal MHC-I delivery from the endosomal recycling compartment to allow cross-presentation. *Cell* **2014**, *158*, 506–521. [[CrossRef](#)] [[PubMed](#)]
110. Beauvillain, C.; Donnou, S.; Jarry, U.; Scotet, M.; Gascan, H.; Delneste, Y.; Guermonprez, P.; Jeannin, P.; Couez, D. Neonatal and adult microglia cross-present exogenous antigens. *Glia* **2008**, *56*, 69–77. [[CrossRef](#)] [[PubMed](#)]
111. Holm, T.H.; Draeby, D.; Owens, T. Microglia are required for astroglial toll-like receptor 4 response and for optimal TLR2 and TLR3 response. *Glia* **2012**, *60*, 630–638. [[CrossRef](#)] [[PubMed](#)]
112. Lin, Y.; Lee, H.; Berg, A.H.; Lisanti, M.P.; Shapiro, L.; Scherer, P.E. The lipopolysaccharide-activated Toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. *J. Biol. Chem.* **2000**, *275*, 24255–24263. [[CrossRef](#)] [[PubMed](#)]

